GILEAD SCIENCES—2021 Transfers of Value made to HCPs and HCOs												
	I	T	ı		T T	T .	I			T .	D	ate of publication: 30/06/2022
	Full Name	HCPs: City of Principal Practice / HCOs: City where registered	Country of Principal Practice	Principal Practice Address	Unique country identifier OPTIONAL		Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)		
	(Art.1.01)	(Art.3)	(Schedule 1)	(Art. 3)	(Art. 3)	Donations and Grants to HCOs / (Art. 3.01.1.a)	Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract	TOTAL OPTIONAL
HCPs	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up. Itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate.											
	OTHER, NOT INCLUDED ABOVE- (where information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount attributable to transfers of value to such Recipients - Art 3.02											
	Number of Recipients in aggregate disclosure - Art 3.02											
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art 3.02											
НС08	INDIVIDUAL NAMED DISCLOSURE- one line per HCO (i.e. all transfers of valued uring a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate.											
	SAA Vogur Hospital	Reykjavik	Icelan d	Storhöfai 45		0,00	0,00	0,00	0,00	114 401 ISK	0,00	114 401 ISK
	OTHER, NOT INCLUDED ABOVE- (where information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount attributable to transfers of value to such Recipients - Art 3.02											
	Number of Recipients in aggregate disclosure - Art 3.02											
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art 3.02					0%	0%	0%	0%	0%	0%	0%
R&D	AGGREGATE DISCLOSURE											
	Transfers of Value re Research & Development as defined in Article 3.04 and Schedule 1											114 401 ISK